Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2855195 | 0.78 | CYP1A2 (0.39) | CYP2C19BLMACE | |
| SCHEMBL2733522 | 0.77 | — | — | |
| SCHEMBL625848 | 0.74 | MGAM (0.35) | — | |
| SCHEMBL13242751 | 0.71 | — | — | |
| SCHEMBL9200803 | 0.71 | GAA (0.38) | — | |
| SCHEMBL22687503 | 0.70 | — | — | |
| SCHEMBL3305213 | 0.70 | CYP2C19 (0.30) | CYP2C19 | |
| SCHEMBL18632488 | 0.69 | POLB (0.34) | POLB | |
| SCHEMBL22023035 | 0.68 | ACE (0.32) | ACE | |
| Acetic Acid SCHEMBL595825 | 0.68 | FFAR3 (0.33) | CYP2C19POLBBLMATMACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948611-B1 | Process for the preparation of a leukotriene antagonist and intermediates thereof | ESTEVE QUIMICA SA (ES) | 2012-05-23 | — | — | EP | disclosed |
| US-20080306270-A1 | Process for the Preparation of a Leukotriene Antagonist and Intermediates Thereof | Esteve Química, S.A. (ES) | 2008-12-11 | — | — | US | disclosed |
| US-20080306270-A1 | Process for the Preparation of a Leukotriene Antagonist and Intermediates Thereof | Esteve Química, S.A. (ES) | 2008-12-11 | — | — | US | disclosed |
| WO-2007051828-A2 | PROCESS FOR THE PREPARATION OF A LEUKOTRIENE ANTAGONIST AND INTERMEDIATES THEREOF | ESTEVE QUÍMICA, S. A. (ES) | 2007-05-10 | — | — | WO | disclosed |
| EP-1783117-A1 | Process for the preparation of a leukotriene antagonist and intermediates thereof | ESTEVE QUIMICA, S.A. (ES) | 2007-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306270-A1 | Process for the Preparation of a Leukotriene Antagonist and Intermediates Thereof | LTC4S, LTB4R, CYSLTR1 | CYP2C19 111/4885POLB 2161/4885BLM 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.